SEARCH:   Advanced

Blood, 15 May 2005, Vol. 105, No. 10, pp. 3802-3811. Prepublished online as a Blood First Edition Paper on February 1, 2005; DOI 10.1182/blood-2004-09-3411. This Article Full Text (PDF) All Versions of this Article: 2004-09-3411v1 105/10/3802    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Curtis, R. E Articles by Deeg, H J Search for Related Content PubMed PubMed Citation Articles by Curtis, R. E Articles by Deeg, H J Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 2, 2004 Accepted December 30, 2004 Impact of chronic GvHD therapy on the development of squamous cell cancers after hematopoietic stem cell transplantation: an international case-control study Rochelle E Curtis*, Catherine Metayer, J D Rizzo, Gerard Socie, Kathleen A Sobocinski, Mary E Flowers, William D Travis, Lois B Travis, Mary M Horowitz, and H J Deeg Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA School of Public Health, University of California, Berkeley, CA, USA Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA Hopital Saint Louis, Hematologie-Greffe de Moelle, Paris, France Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA Armed Forces Institute of Pathology, Washington, DC, USA * Corresponding author; email: rcurtis{at}mail.nih.gov. Previous studies of hematopoietic stem cell transplant (HCT) recipients suggest that graft-versus-host disease (GvHD) and its therapy may increase the risk of solid cancers, particularly squamous cell carcinomas (SCC) of the buccal cavity and skin. However, the importance and magnitude of these associations are not well characterized. We conducted a case-control study of 183 patients with post-transplant solid cancers (58 SCC, 125 non-SCC) and 501 matched controls within a cohort of 24,011 patients who received HCT at 215 centers worldwide. Our results showed that chronic GvHD and its therapy were strongly related to the risk of SCC, whereas no increase in risk was found for non-SCC cancers. Long duration of chronic GvHD therapy (p=0.0001), the use of azathioprine, particularly when combined with cyclosporine and steroids (p= 0.0002), and severe chronic GvHD (p=0.004) were identified as major risk factors for the development of SCC. Since most patients who received prolonged immunosuppressive therapy and those with severe chronic GvHD were also treated with azathioprine, the independent effects of these factors could not be evaluated. Additional analyses determined that prolonged immunosuppressive therapy and the use of azathioprine were also significant risk factors for SCC of the skin and of the oral mucosa. These data provide further encouragement to strategies to prevent chronic GHVD, and for those patients with moderate/severe chronic GvHD, the development of more effective and less carcinogenic treatment regimens. Our results also suggest that clinical screening for SCC is appropriate among patients exposed to persistent chronic GVHD, prolonged immunosuppressive therapy, or both. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Nguyen, P. M. Vacek, P. O'Neill, R. B. Colletti, and B. A. Finette Mutagenicity and Potential Carcinogenicity of Thiopurine Treatment in Patients with Inflammatory Bowel Disease Cancer Res., September 1, 2009; 69(17): 7004 - 7012. [Abstract] [Full Text] [PDF] M. M. Imanguli, W. D. Swaim, S. C. League, R. E. Gress, S. Z. Pavletic, and F. T. Hakim Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa Blood, April 9, 2009; 113(15): 3620 - 3630. [Abstract] [Full Text] [PDF] B. N. Savani, S. Goodman, and A. J. Barrett Can Routine Posttransplant HPV Vaccination Prevent Commonly Occurring Epithelial Cancers after Allogeneic Stem Cell Transplantation? Clin. Cancer Res., April 1, 2009; 15(7): 2219 - 2221. [Abstract] [Full Text] [PDF] A. Janin, H. Murata, C. Leboeuf, J.-M. Cayuela, E. Gluckman, L. Legres, A. Desveaux, M. Varna, P. Ratajczak, J. Soulier, et al. Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation Blood, February 19, 2009; 113(8): 1834 - 1840. [Abstract] [Full Text] [PDF] J. D. Rizzo, R. E. Curtis, G. Socie, K. A. Sobocinski, E. Gilbert, O. Landgren, L. B. Travis, W. D. Travis, M. E. D. Flowers, D. L. Friedman, et al. Solid cancers after allogeneic hematopoietic cell transplantation Blood, January 29, 2009; 113(5): 1175 - 1183. [Abstract] [Full Text] [PDF] D. L. Friedman, A. Rovo, W. Leisenring, A. Locasciulli, M. E. D. Flowers, A. Tichelli, J. E. Sanders, H. J. Deeg, and G. Socie Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party Blood, January 15, 2008; 111(2): 939 - 944. [Abstract] [Full Text] [PDF] S. J. Lee and M. E. D. Flowers Recognizing and Managing Chronic Graft-Versus-Host Disease Hematology, January 1, 2008; 2008(1): 134 - 141. [Abstract] [Full Text] [PDF] N. S. Majhail Old and New Cancers after Hematopoietic-Cell Transplantation Hematology, January 1, 2008; 2008(1): 142 - 149. [Abstract] [Full Text] [PDF] K. H. T. Paraiso, T. Ghansah, A. Costello, R. W. Engelman, and W. G. Kerr Induced SHIP Deficiency Expands Myeloid Regulatory Cells and Abrogates Graft-versus-Host Disease J. Immunol., March 1, 2007; 178(5): 2893 - 2900. [Abstract] [Full Text] [PDF] G. Socie Predicting secondary malignancies after allogeneic transplantation? Blood, April 15, 2006; 107(8): 3022 - 3023. [Full Text] [PDF] P. Faber, P. Fisch, M. Waterhouse, A. Schmitt-Graff, H. Bertz, J. Finke, and A. Spyridonidis Frequent genomic alterations in epithelium measured by microsatellite instability following allogeneic hematopoietic cell transplantation in humans Blood, April 15, 2006; 107(8): 3389 - 3396. [Abstract] [Full Text] [PDF] W. Leisenring, D. L. Friedman, M. E.D. Flowers, J. L. Schwartz, and H. J. Deeg Nonmelanoma Skin and Mucosal Cancers After Hematopoietic Cell Transplantation J. Clin. Oncol., March 1, 2006; 24(7): 1119 - 1126. [Abstract] [Full Text] [PDF] A. Tichelli and G. Socie Considerations for Adult Cancer Survivors Hematology, January 1, 2005; 2005(1): 516 - 522. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020